Philippe Labrune
Pediatrics — Hôpital Antoine-Béclère, France
Philippe Labrune
LeadR Profile
Pediatrics
Subspecialties: Genetics - Hepatology - Neurology
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1989 - 2026
Number : 293
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Prospective gait analysis in patients from the French registry of glycogen storage disease type III: implications for clinical trials. registries, glycogen, glycogen storage disease, muscles, gait analysis, gait, neurosurgery, walking, neurology, glycogen storage disease type iii | J Neurol | 2026 | 0 |
| Imlifidase enables AAV gene therapy in a seropositive Crigler-Najjar patient: On the verge of a paradigm shift. genes, therapeutics, genetic therapy | Mol Ther | 2026 | 0 |
| Expert-Designed Fact Sheets and AI-Based Analysis of Patient Symptoms to Combat Diagnostic Delays in Inherited Metabolic Diseases. metabolic diseases, delayed diagnosis, signs and symptoms, diagnosis, artificial intelligence | J Inherit Metab Dis | 2026 | 0 |
| Impact of COVID-19 infection in patients with inherited metabolic diseases: a National Multicenter Study from the French IMDs Healthcare Network for Rare Diseases. rare diseases, metabolic diseases, covid-19, infections | Orphanet J Rare Dis | 2026 | 0 |
| Enhanced lysosomal glycogen breakdown is associated with liver tumorigenesis in glycogen storage disease type III. liver diseases, glycogen, carcinoma, hepatocellular, growth, glycogen storage disease, rare diseases, fibrosis, neoplasms, liver, liver neoplasms, carcinogenesis, therapeutics, liver glycogen, glycogen storage disease type iii | JHEP Rep | 2025 | 0 |
Clinical Studies 7
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 10
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Efficacy and Safety of GNT0003 Following Imlifidase Pre treatment in Severe Crigler Najjar Syndrome NCT06518005 — genes, safety, powders, antibodies, administration, intravenous, crigler-najjar syndrome, transgenes, solutions, phototherapy, transplants, therapeutics, consent forms, cardiomyopathies, bilirubin | Phase 2 | Recruiting | 2024 |
LeadR Networks
Main global connection map